AWL-II-38.3

• UNSPSC Description:

  AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf[1][2][1][2].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/awl-ii-38-3.html

• Purity:

  99.71

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=NO1)NC2=CC(NC(C3=CC(C(F)(F)F)=CC(N4C=NC(C)=C4)=C3)=O)=CC=C2C

• Molecular Weight:

  469.42

• References & Citations:

  [1] Yongmun Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70.|[2]Efrat Mashiach-Farkash, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1135205-94-5